Establishing a clinical program for human immunodeficiency virus 1-seropositive men to father seronegative children by means of in vitro fertilization with intracytoplasmic sperm injection

Am J Obstet Gynecol. 2002 Apr;186(4):627-33. doi: 10.1067/mob.2002.122125.

Abstract

Objective: We assessed the safety and efficacy of providing assisted reproduction to men who are seropositive for human immunodeficiency virus type 1 (HIV-1).

Study design: HIV-1-serodiscordant couples underwent in vitro fertilization with intracytoplasmic sperm injection (IVF-ICSI). Patients were screened for HIV-1 3 and 6 months after embryo transfer to determine safety. Infants and mothers were tested at delivery and at 3 months after delivery. Clinical outcomes were compared with those of matched control couples who had undergone IVF-ICSI to measure efficacy.

Results: There were no seroconversions in women (n = 34) or offspring (n = 25) after 55 embryo transfers. Treatment efficacy was similar to that for control couples: retrieved eggs (15.8 +/- 1.3 vs 12.3 +/- 0.8); fertilization rate (64.9% vs 68.0%); embryos cryopreserved (1.1 +/- 0.3 vs 0.3 +/- 0.1, P <.05); clinical pregnancies per embryo transfer (45.5% vs 35.4%); ongoing or delivered pregnancies per embryo transfer (30.9% vs 25.0%).

Conclusion: Although findings are preliminary, IVF-ICSI provides HIV-1-serodiscordant couples with a reasonably safe means of having children because their assisted reproduction performance is similar to that of conventional patients.

MeSH terms

  • Acquired Immunodeficiency Syndrome / prevention & control
  • Acquired Immunodeficiency Syndrome / transmission
  • Adult
  • Cohort Studies
  • Embryo Transfer
  • Fathers*
  • Female
  • HIV Seronegativity*
  • HIV Seropositivity*
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Pregnancy
  • Prospective Studies
  • Software
  • Sperm Injections, Intracytoplasmic*
  • Treatment Outcome